Therapy For Edema Reduction
- Detailed Technology Description
- None
- Supplementary Information
- Patent Number: US20130115267A1
Application Number: US13666773A
Inventor: ROGERS, Victor G.J. | BINDER, Devin | McBRIDE, Devin | HSU, Michael | PARK, B. Hyle
Priority Date: 3 Nov 2011
Priority Number: US20130115267A1
Application Date: 1 Nov 2012
Publication Date: 9 May 2013
IPC Current: A61M002500 | A61K003838 | A61M002514 | A61P004300
US Class: 424443 | 424400 | 5140011
Assignee Applicant: The Regents of the University of California
Title: COMPOSITIONS AND METHODS FOR REDUCING EDEMA
Usefulness: COMPOSITIONS AND METHODS FOR REDUCING EDEMA
Summary: For removing edema; and fluid or water from a tissue, edematous/injured or burned/central nervous system (CNS)/spinal or brain tissue, brain injury or burn edema, to treat or ameliorate CNS/spinal or cerebral edema, spinal or brain inflammation, or CNS/spinal or brain injury (Claimed).
Novelty: Product or device useful for reducing edema, comprises protein/carbohydrate/polysaccharide/polymer solution which is optionally concentrated, or non-rigid hydrogel/gel, and concentrated osmolyte solution/rejected solute
- Industry
- Biomedical
- Sub Category
- Medical Composition
- Application No.
- 20150141950
- Others
-
Tech ID/UC Case
21125/2010-962-0
Related Cases
2010-962-0
- *Abstract
-
TBI is the foremost cause of morbidity and mortality in persons under 45 years of age worldwide, and accounts for a larger number of casualties in combat in Iraq and Afghanistan than in any other recent U.S. war. After TBI, many patients experience a delayed rise in intracranial pressure due to cerebral edema, leading to reduced cerebral blood flow, brain herniation, and death. UCR’s Professor Victor Rodgers and his collaborators have developed a novel process for direct treatment and reversal of brain edema.
This new technique exploits the inevitable osmotic pressure that is generated during transport of proteins or polymers across a semi-permeable membrane in the presence of aqueous systems.
A significant amount of long-term morbidity associated with TBI can be prevented if more effective therapies to minimize cerebral edema such as this could be developed, both for use in the combat field and in civilian hospitals.
The mission of UCR’s Office of Technology Commercialization (OTC) is to insure that research results are made available for public use and benefit. For this purpose, OTC is currently marketing this technology to industry.
- *IP Issue Date
- May 21, 2015
- *Principal Investigator
-
Name: Devin McBride
Department:
Name: Victor G.J. Rodgers
Department:
Name: Devin Binder
Department:
Name: Hyle Park
Department:
Name: Michael Hsu
Department:
- Country/Region
- USA
